Using nanoparticles to deliver cancer-fighting microRNA for colon cancer treatment
Self-immolative prodrug/miRNA nanoparticle combinations for cancer treatment
This study is testing a new way to deliver cancer-fighting molecules directly to colon cancer cells using tiny particles that break down inside the cells, which could lead to better treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-10672877 on NIH RePORTER |
What this research studies
This research focuses on developing innovative nanoparticles that can effectively deliver anticancer microRNA (miRNA) specifically targeting colon cancer cells. The approach involves creating self-assembled nanomaterials that not only transport the miRNA but also degrade within the cancer cells to release small molecules that help regulate polyamine metabolism, which is often disrupted in cancer. By combining these nanoparticles with miRNA therapy, the research aims to enhance the effectiveness of cancer treatment and overcome existing challenges in delivering miRNA therapeutics. Patients may benefit from a more effective treatment option that targets the underlying mechanisms of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with colon cancer who are seeking new treatment options.
Not a fit: Patients with cancers other than colon cancer or those who are not eligible for experimental therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with colon cancer.
How similar studies have performed: Other research has shown promising results using similar nanoparticle delivery systems for cancer therapies, indicating potential for success in this approach.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Oupicky, David — University of Nebraska Medical Center
- Study coordinator: Oupicky, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.